Pular para o conteúdo principal
Ranking Invest

CTKB - Cytek Biosciences, Inc.

Segmento: HealthcareCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Análise Ranking Invest

Valuation estimado
$ 223.51 Mi
Valor de Mercado
$ 598.57 Mi
Sobrepreço (AV)+167.8%
IVR
0.37A companhia vale 0,37 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.18O valuation alternativo equivale a -18% do valor de mercado da companhia.
MLL
-0.18O lucro líquido dos controladores em 16 trimestres equivale a -18% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 321.95 Mi

Dívida Líquida

-$ 73.85 Mi

L4T

-$ 80.58 Mi

MM4T

-37.35%

Indicadores Básicos

ROE

-25.03%

Índices de Previsibilidade

Receita Líquida

D0.11

Lucro

F2.79

Margem

G29.35

Índices de Tendência

Receita Líquida

C3.78

Lucro

F-6.19

Margem

F-6.76

Índices de Endividamento

DIV/PAT

-0.23

DIV/L4T

0.92

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.